Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice

Glucagon-like peptide-1 (GLP-1) has been proved to have effects of anti-hyperglycemia and β-cell preservation. However, it is still unclear whether there are differences between early and late GLP-1 intervention in type 2 diabetes mellitus (T2DM). We divided the mice into 5 groups: early treated group (n = 7, 8-week old, fasting glucose > 10 mmol/l), late treated group (n = 7, 10-week old, fasting glucose > 20 mmol/l), early control group (n = 7), late control group (n = 7) and wild type group (n = 7). Treated group was injected with liraglutide (a GLP-1 analog) 300 μg/kg bid for 4 weeks, while control group was given saline at the same time. The results showed that compared with control group, food intake and body weight gain were reduced in both early and late treated group (p < 0.05), and there was no significance between the two treated groups. Early liraglutide intervention showed better improvements in glucose control, acute insulin response to glucose (AIRg) and disposition index (before vs. after treatment, AIRg 1.01 ± 0.53 vs. 2.98 ± 0.63, disposition index 10.81 ± 0.89 vs. 27.4 ± 2.15) than late intervention (AIRg 0.99 ± 0.02 vs. 1.41 ± 0.32, disposition index 3.47 ± 0.38 vs. 6.43 ± 1.62, p = 0.001). The histopathology of the pancreas showed the estimated β-cell mass (BCM) was increased more in early treated group than that in late one (0.03 vs. 0.01 g). Expressions of the proliferation related genes PDX-1, MafA and GLP-1 receptor (GLP-1R) in early treated group were 1.81, 2.57 and 1.59 times as much as that in late treated group. In conclusion, early liraglutide intervention was better in glucose control, β-cell function improvement and β-cell mass preservation.     

Comparison of patient and staff temple dose during fluoroscopically guided coronary angiography,implantable cardiac devices,and electrophysiology procedures

There is a paucity of literature comparing patient and staff dose during coronary angiography (CA), implantable cardiac devices, permanent pacemakers (PPM) and electrophysiology (EP) procedures and little noting dose to staff other than cardiologists. This study sought to compare patient and occupational dose during a range of fluoroscopically guided cardiac procedures. Radiation dose levels for the patients (n = 1651), cardiologists (n = 24), scrub (n = 32) and scout nurses (n = 35) were measured in a prospective single-centre study between February 2017 and August 2019. A comparison of dose during CA, device implantation, PPM insertion and EP studies was performed. Three angiographic units were used, with dosimeters worn on the temple of staff. Results indicated that occupational dose during PPM was significantly higher than other procedures. The cardiologist had the highest mean dose during biventricular implantable cardioverter-defibrillators; levels were approximately five times that of ‘normal’ pacemaker insertions. Transcatheter aortic valve implantations (TAVI) were associated with relatively high mean doses for both staff and patients and had a statistically significant higher (>2 times) mean patient dose area product than all other categories. TAVI workups were also related to higher mean cardiologist and scrub nurse dose. It was observed that the mean scrub nurse dose can exceed that of the cardiologist. The highest mean dose for Scout nurses were recorded during EP studies. Given the significantly higher temple dose associated with PPM insertion, cardiologists should consider utilizing ceiling mounted lead shields, lead glasses and/or skull caps where possible. Efforts should also be made to minimize the use of DSA during TAVI and TAVI workups to reduce cardiologist, nurse and patient dose.     

Post‐GWAS in Psychiatric Genetics: A Developmental Perspective on the “Other” Next Steps

As psychiatric genetics enters an era where gene identification is finally yielding robust, replicable genetic associations and polygenic risk scores, it is important to consider next steps and delineate how that knowledge will be applied to ultimately ameliorate suffering associated with substance use and psychiatric disorders. Much of the post‐genome‐wide association study discussion has focused on the potential of genetic information to elucidate the underlying biology and use this information for the development of more effective pharmaceutical treatments. In this review we focus on additional areas of research that should follow gene identification. By taking genetic findings into longitudinal, developmental studies, we can map the pathways by which genetic risk manifests across development, elucidating the early behavioral manifestations of risk, and studying how various environments and interventions moderate that risk across developmental stages. The delineation of risk across development will advance our understanding of mechanism, sex differences and risk and resilience processes in different racial/ethnic groups. Here, we review how the extant twin study literature can be used to guide these efforts. Together, these new lines of research will enable us to develop more informed, tailored prevention and intervention efforts.     

低位胆道恶性梗阻性黄疸术前胆红素异常的处理策略探讨(附134例报告)

目的:探讨低位胆道恶性梗阻性黄疸患者术前胆红素异常的处理策略,以提高该类患者的临床疗效。方法:回顾性分析西京医院肝胆外科2008年1月1日-2017年12月31日收治的符合研究条件的134例低位胆道恶性梗阻性黄疸(术前总胆红素≥171μmol/L)患者,按胆红素水平分为中、重度黄疸组,分析和比较两组术前黄疸的处理方法、术后肝功能、并发症情况等。结果:两组患者胆道引流后总胆红素水平均明显低于引流前,而肝功能Child-Pugh分级比较差异均无统计学意义(P0.05);两组行术前胆道引流患者与未行胆道引流患者的围手术期情况比较均无统计学差异(P0.05);两组行术前胆道引流患者与未行胆道引流患者的手术并发症的发生情况比较均无统计学差异(P0.05)。结论:对于低位胆道恶性梗阻性黄疸患者,无论中度黄疸还是重度黄疸,原则上术前不必行胆道引流。对于伴有脏器功能不全、急性炎症或其他暂不宜手术的患者,可先行胆道引流处理,限期手术。若行术前胆道引流,采用PTCD方式,更为简单安全有效。     

有无心脏外科支持的经皮冠状动脉介入术病例特点及转归的比较分析

目的:分析有无心脏外科支持的经皮冠状动脉介入术(PCI)病例的特点及转归差异。方法:回顾性分析2308例行PCI术患者的病例资料,根据心脏外科支持情况分为支持组(2031例)、无支持组(277例),比较两组患者的基线资料、PCI术相关指标及主要不良心血管事件(MACE)的发生情况。结果:与支持组比较,无支持组患者的医疗费用明显增加,急诊PCI、危险因素中AMI病史、PCI史、疾病诊断中STEMI的比例明显降低,LVEF明显升高,差异均有统计学意义(P0.05)。支持组以三支及以上冠脉病变以及B、C型复杂病变形态多见,支架置入数、左主干病变比例明显增多,靶血管IVUS比例检查比例、术中总并发症发生率明显降低,与无支持组比较差异均有统计学意义(P0.05)。两组PCI术后MACE的发生率比较差异均无统计学意义(P0.05)。结论:有无心脏外科支持的PCI患者的临床特点存在较大差异,无心脏外科支持的PCI患者以急诊手术为主,且靶血管病变相对较轻。对于低风险病例实施PCI手术是安全可行的,具有较高成功率,预后尚可。     

A Simple Method for Measuring the Changeable Mechanical Action of Unloader Knee Braces for Osteoarthritis

Purpose

Today's orthotics should be designed to apply the external orthosis moment to the knee joint solely during the stance phase instead of the entire gait cycle. The aim of this study was to validate the reliability of a simple device for measuring forces at the leg–orthosis interface and describe the behavior of an innovating dynamic unloader knee brace built to interrupt its mechanical action during large knee flexion (swing phase of gait).

不同运动干预方式对糖尿病前期人群血糖相关指标影响的Meta分析

目的：系统评价有氧运动、抗阻运动、有氧联合抗阻运动三种不同干预方式对糖尿病前期人群血糖的影响。方法：制定文献检索策略,检索PubMed、EMBASE、EBSCO外文数据库以及CNKI、Wanfang中文数据库,以手工查阅检出文献和相关参考文献作为补充,查找符合纳入标准的随机对照试验进行质量评价,运用RevMan5.2统计软件对纳入的数据进行Meta分析,运动干预组和对照组间指标采用均数差（MD）评价。结果：共纳入原始文献8篇,与对照组相比,不同运动干预方式的综合效应对空腹血糖指标无显著性影响,与按不同干预方式进行亚组分析结果一致;有氧运动及有氧联合抗阻运动对餐后2h血糖指标有显著性降低的作用（P < 0.05）;有氧运动对胰岛素抵抗指数有显著降低作用。结论：对糖尿病前期人群,运动干预对餐后2 h血糖、胰岛素抵抗指数的影响与运动方式有关,但对空腹血糖的作用尚不能确定。